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Abstract
Trypanosoma cruzi, the protozoan parasite that causes Chagas dis-
ease, does not synthesize sialic acid, but expresses a trans-sialidase
(TS) that catalyzes the transfer of sialic acid from host glycoconjugates
to the parasite surface. Here, we review studies that characterize the
immune response to the catalytic domain of the enzyme in humans
during Chagas disease or in mice following immunization with the
TS gene. In both cases, there are antibodies that strongly inhibit the
enzymatic activity and generation of interferon-g-producing T cells.
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Chagas’ disease
Trypanosoma cruzi is a protozoan para-
site and the causative agent of Chagas dis-
ease. In spite of considerable efforts to eradi-
cate the triatomine, the disease is still trans-
mitted in several states of Brazil and other
South American countries, endangering mil-
lions of people. Also, the existence of 10-14
million individuals in the chronic stages of
the disease is a major threat for transmission
through blood transfusion.
After contact with trypomastigotes of T.
cruzi, mammalian hosts develop the acute
phase of Chagas disease, characterized by
patent parasitemia that lasts for several weeks.
The chronic phase initiates when the para-
sitemia declines significantly, becoming sub-
clinical. Most individuals carry this infec-
tion for life. Drug treatment is prolonged and
its efficacy is not high. In recently infected
children, treatment is 55.8% efficient (1).
The efficacy is even lower (19.1%) in adults
infected for many years (2). The poor pros-
pect of treatment raises the possibility that
immune interventions, such as immuniza-
tion, could be an additional weapon to in-
crease treatment efficacy in patients who do
not respond to conventional chemotherapy.
Structure of the trans-sialidase
Several surface antigens of infective forms
of T. cruzi (trypomastigotes and amastigotes)
have been grouped into a super-family de-
fined by the presence of consensus sequences
homologous to bacterial sialidases (3-5).
These surface antigens are a highly polymor-
phic family of proteins with molecular masses
ranging from 85 to 200 kDa. Many of these
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proteins have been implicated in a number of
biological processes important for T. cruzi
interaction with host cells and extra-cellular
matrix proteins (6-11). One group of these
proteins are enzymes denominated trans-
sialidase (TS) that catalyze the transfer of
sialic acid to ß-galactosyl residues of mucin-
like glycoproteins that are present on the
surface of T. cruzi trypomastigotes and
epimastigotes (12,13).
The importance of the acquisition of sialic
acid is not completely known. However,
there are suggestions that the transfer of
sialic acid present on the surface of the host
cell to the parasite may help trypomastigote
adhesion and penetration into nonphagocytic
cells (9,14). Sialic acid also provides a
strongly negatively charged cover that pro-
tects parasites against human lytic antibod-
ies specific for a-galactosyl residues which
are abundant on the trypomastigote surface
(Pereira-Chiccola VL, Acosta-Serrano A,
Almeida I, Rodrigues MM, Travassos LR
and Schenkman S, unpublished results).
In trypomastigote forms found in the ver-
tebrate host, TS is formed by multimeric
aggregates with molecular mass ³400 kDa
(15,16), that upon denaturation migrates as
multiple bands ranging from 160 to 220 kDa
in SDS-PAGE (13,17). Trypomastigote TS
has essentially 2 different domains. The N-
terminal region contains the catalytic do-
main of the enzyme (Ref. 18 and Figure 1).
The C-terminal, or CTR, is composed of
amino acid repetitions. TS is linked to the
parasite membrane by a glycosyl-phosphati-
dylinositol (GPI) anchor and is continuously
shed into the supernatant. Details concern-
ing the TS gene and its protein structure have
been described by Schenkman et al. (5).
Immunogenic properties of TS during
human infection with T. cruzi
Serological studies have shown that TS is
highly immunogenic during natural human
infection with T. cruzi. Almost all individuals
develop antibodies that recognize an epitope
within the CTR of TS (3). Chagasic patients
also generate antibodies specific for the N-
terminal region of TS that strongly inhibit its
enzymatic activity (19,20). Comparatively,
chagasic antibodies preferentially recognize
the native TS which contains the CTR rather
than a recombinant TS which contains only
the N-terminal catalytic domain (Figure 2).
Nevertheless, there is direct evidence that
inhibitory antibodies which recognize the cata-
lytic domain of TS passively protect mice
against bloodstream trypomastigote infection
(21). These inhibitory antibodies differ from
antibodies against the CTR that are unable to
block enzymatic activity and were not re-
ported as protective (21,22).
To complement these serological studies,
we used a recombinant protein based on the
sequence of the N-terminal catalytic domain
to determine whether chagasic patients de-
velop a cell-mediated immune response (CMI)
to TS. CMI was measured by in vitro T-cell
proliferation, and interferon-g and interleu-
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Figure 1 - Schematic view of
the trans-sialidase (TS) of T.
cruzi trypomastigotes and the
recombinant protein based on
the N-terminal region.
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ognition of native and recombi-
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by ELISA.
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kin-4 production in response to the recombi-
nant protein. We found that cells from 78% of
the chagasic patients proliferated in response
to the recombinant TS. Most relevant, cells
from 88% of these patients produced inter-
feron-g upon stimulation with the recombi-
nant protein (Figure 3 and Ribeirªo M, Pereira-
Chiccola VL, Fragata-Filho A, Renia L,
Schenkman S and Rodrigues MM, unpub-
lished results). In contrast, interleukin-4 was
not detected in response to TS. CMI was
specific, because healthy individuals never
exposed to T. cruzi infection failed to react
with this recombinant protein. From these
results, we concluded that the TS catalytic
domain is recognized by T cells and antibod-
ies in a large proportion of patients infected
with T. cruzi.
Immunogenic properties of TS
delivered as naked DNA vaccine
Based on the results that support the con-
cept that TS is highly immunogenic during
natural infection with T. cruzi, we deter-
mined whether immunization with plasmids
containing the TS gene could elicit immu-
nity against experimental Chagas disease.
Initially we compared the immunogenicity
of several plasmid vectors containing a gene
encoding the catalytic domain of TS. Addi-
tionally, we evaluated the effect of the pres-
ence or absence of the signal peptide on the
immunization with plasmid DNA. For this
purpose, three plasmids were generated con-
taining the coding region for the catalytic
domain of TS. The TS gene was inserted into
Table 1 - Antibody induction by immunization with TS plasmids.
1Based on the sequence of gene TS 154 cloned from T. cruzi Y strain (17). Length is reported in terms of
number of amino acid residues (aa).
Plasmid Vector Translated amino acids1 Length (aa) Antibody titers Inhibition of TS activity
B43 pcDNA3 33-678 645 1.63 x 104 72 ± 21
154/13 pcDNA3 1-678 678 1.69 x 104 86 ± 13
Cl-44 VR1012 1-678 678 1.68 x 104 64 ± 27
pcDNA3 pcDNA3 - - <1:100 11 ± 7
VR1012 VR1012 - - <1:100 1.3 ± 3.3
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Figure 3 - Proliferative re-
sponse and interferon-g pro-
duction by peripheral blood
mononuclear cells of a cha-
gasic patient upon stimula-
tion with recombinant trans-
sialidase (TS).
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the pcDNA3 vector with or without the cod-
ing region for the TS signal peptide. These
plasmids were found to be equally immuno-
genic by inducing antibodies to TS as esti-
mated by ELISA or inhibition of TS enzy-
matic activity (Table 1 and Ref. 23).
Subsequently, we used one of these plas-
mids to determine whether the TS gene could
elicit T cell-mediated and protective immu-
nity against T. cruzi infection in mice. BALB/
c mice immunized with plasmid 154/13 con-
taining the gene encoding the catalytic do-
main of trans-sialidase generated specific
immune responses, as measured by antibody
production and T cell activation (24). Al-
though the major immunoglobulin G pro-
duced in response to the TS gene was IgG1,
we noticed that T cells preferentially pro-
duced interferon-g. To understand this ap-
parent contradiction, we derived T cell clones
from DNA-immunized mice. We found that
CD4+ T cell clones produced high levels of
interferon-g but failed to secrete IL-4 or IL-
10 (TH1 cells). In addition, we isolated CD4+
T cell clones that secreted IL-4 and IL-10 but
failed to produce interferon-g (TH2 cells,
Rodrigues MM, Ribeirªo M, Pereira-
Chiccola VL, Renia L, Schenkman S and
Costa F, unpublished results). Our results
demonstrate that TH1 and TH2 CD4+ cells
coexist in mice immunized with the TS gene.
In addition to interferon-g-producing
CD4+ T cells, we demonstrated that 35% of
the interferon-g secreted came from CD8+ T
cells. To confirm the existence of this T cell
subtype, we also generated T cell clones
using as target cells A20J cells transfected
with the TS gene. These clones produce
large amounts of interferon-g upon stimula-
tion with TS-transfected syngeneic cells.
Considering that interferon-g has been im-
plicated in resistance against T. cruzi infec-
tion (25), it is quite possible that both cell
types mediated protective immunity in our
model. In support of this hypothesis, we
observed that upon challenge with blood
stages of T. cruzi, BALB/c mice showed a
significant reduction in the peak of para-
sitemia (24). Most relevant, 87% of these
animals survived the acute infection induced
by blood stages of T. cruzi. In contrast, there
was only 10% survival in control mice im-
munized with the vector alone (Table 2). The
protective immunity observed in BALB/c
mice was strain specific since A/Sn mice
immunized with this same plasmid failed to
survive the infection.
Conclusions
The molecular characterization of T. cruzi
TS opened the possibility of designing ex-
periments to study naturally acquired human
immunity and to compare it with immunity
elicited by vaccination in the experimental
models. Our data strongly suggest that im-
munity to TS is deleterious to the parasite,
protecting the host. In the experimental
model, a similar immunity pattern can be
obtained by immunization with a naked DNA
vaccine, inducing the production of inhibi-
tory antibodies, as well as the activation of
interferon-g-producing T cells. Although this
is clearly a protective response, protective
immunity depends on the genetic background
of the host. Future studies may reveal whether
immunity to TS also contributes to the pa-
thology of chronic Chagas disease in hu-
mans.
Table 2 - Survival of BALB/c and A/Sn mice after challenge with T. cruzi
trypomastigotes.
Mice were immunized with 4 doses of the indicated plasmid. Each dose consisted of
100 µg of DNA per animal. BALB/c and A/Sn mice were challenged with 6,500 and 250
T. cruzi trypomastigotes, respectively.
Mouse strain Plasmid Number of Number of mice Protection (%)
experiments (protected/challenged)
BALB/c PCDNA3 3 2/20 10%
BALB/c 154/13 3 20/23 87%
A/Sn PCDNA3 3 0/15 0%
A/Sn 154/13 3 0/15 0%
A/Sn VR1012 2 0/10 0%
A/Sn Cl-44 2 0/8 0%
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